But nearly half of Merck's revenue is generated by a single product. That's oncology drug Keytruda, which has turned out to ...

Merck & Co., Inc. (NYSE:MRK) is one of the stocks Jim Cramer discussed, along with the tech battleground. Cramer highlighted ...

Merck (MRK)’s stock surged by 41%, driven not significantly by revenue but rather by increased profits and heightened ...

Merck has outperformed the healthcare sector over the past three months. Moreover, Wall Street analysts are moderately ...

Merck demonstrates excellence across the board through its resilient revenue mix, expanding profitability, and stellar ...

Merck & Co has a lower P/E than the aggregate P/E of 57.45 of the Pharmaceuticals industry. Ideally, one might believe that ...

Surging stock prices and earnings growth potential make Meta Platforms, ASML, and Eli Lilly ripe for stock splits in the new ...

On December 4, 2025, Merck & Co., Inc. completed a significant financial maneuver by closing an underwritten public offering of various notes totaling $7 billion. This strategic move is expected to ...

Finally, Merck is a terrific dividend stock that has increased its payouts by 84.7% over the past decade and currently offers a forward yield of 3.5%. It may not be a stock to buy for explosive growth ...

Merck stock has reached a notable milestone, hitting a 52-week high of 105.08 USD. This peak marks a significant point for the pharmaceutical giant, reflecting investor confidence and market momentum.

Merck (MRK) has quietly pulled ahead of many pharma peers, with the stock climbing about 22% over the past month and 20% in ...

Len Yaffee says Eli Lilly stock will find it hard to push any higher from here. The Kassef Capital's chief executive ...